Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 3,192 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total transaction of $51,072.00. Following the transaction, the chief financial officer now owns 13,422 shares in the company, valued at $214,752. The sale was disclosed in a filing with the SEC, which is available through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, December 24th, Michael Burkes Brophy sold 449 shares of Natera stock. The stock was sold at an average price of $12.39, for a total transaction of $5,563.11.
Shares of NTRA stock traded up $0.22 during mid-day trading on Friday, hitting $19.14. 18,084 shares of the stock traded hands, compared to its average volume of 610,960. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -9.00 and a beta of 1.84. Natera Inc has a 52-week low of $8.60 and a 52-week high of $29.62. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44.
Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, March 12th. The medical research company reported ($0.51) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.51). The firm had revenue of $67.00 million during the quarter, compared to analyst estimates of $62.87 million. Natera had a negative net margin of 49.72% and a negative return on equity of 1,214.02%. As a group, equities analysts predict that Natera Inc will post -1.59 earnings per share for the current fiscal year.
Several research firms have commented on NTRA. Zacks Investment Research raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Saturday, March 2nd. BidaskClub lowered shares of Natera from a “sell” rating to a “strong sell” rating in a research report on Friday, March 1st. ValuEngine raised shares of Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, January 15th. Finally, Canaccord Genuity reissued a “buy” rating and set a $25.00 price target on shares of Natera in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $27.75.
Several institutional investors have recently made changes to their positions in NTRA. FMR LLC purchased a new position in shares of Natera in the 3rd quarter valued at approximately $59,599,000. Jennison Associates LLC grew its stake in shares of Natera by 39.1% during the 3rd quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock worth $87,186,000 after purchasing an additional 1,024,225 shares during the period. Vanguard Group Inc grew its stake in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares during the period. Vanguard Group Inc. grew its stake in shares of Natera by 28.9% during the 3rd quarter. Vanguard Group Inc. now owns 3,612,860 shares of the medical research company’s stock worth $86,493,000 after purchasing an additional 808,976 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Natera by 92.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,528,400 shares of the medical research company’s stock worth $36,590,000 after purchasing an additional 736,000 shares during the period. 90.05% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Natera Inc (NTRA) CFO Sells $51,072.00 in Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2019/03/15/insider-selling-natera-inc-ntra-cfo-sells-51072-00-in-stock.html.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: What is the Coverage Ratio?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.